Fixed-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-1)
Not Recruiting
40 years - 80 years
All
Phase
3
5 participants needed
1 Location
Brief description of study
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics of 2 fixed doses of tavapadon and placebo in participants with early Parkinson's Disease
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Parkinson's Disease
-
Age: 40 years - 80 years
-
Gender: All
Male and female age 40-80 Diagnosis of Parkinson's Disease
Updated on
01 Aug 2024.
Study ID: 843327
